Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06620458

A Retrospective Study on the Factors of Drug-coated Balloon Restenosis

The purpose of this study is to analyze potential factors post paclitaxel drug-coated balloon angioplasty in patients with Denovo large vessels disease. It includes imaging endpoints and clinical event endpoints. Over 5000 patients are expected to be enrolled.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Fuwai Central China Cardiovascular Hospital

Zhengzhou, 450003, China

Location status: Recruiting

Location contact

Quan Guo

CONTACT

[email protected]

15670510031

About this study

This study is a retrospective analysis that retrospectively reviewed over approximately 5000 patients with de novo-large-vessel disease who underwent paclitaxel drug-coated balloon angioplasty. The study endpoints include cardiovascular adverse events at 1 year (cardiovascular death, cardiovascular events) and coronary angiographic outcomes (primarily late lumen loss, restenosis rate). It primarily focuses on differences in baseline characteristics, lesion features, intracavitary imaging characteristics(Including OCT, IVUS), hemodynamic parameter,and procedural approaches among patients. Over 5000 patients are expected to be enrolled.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age:

18 years and older.

  • Diagnosis:

Diagnosed with coronary artery disease with native large vessel lesions confirmed by coronary angiography.

  • Treatment Plan:

Scheduled to receive paclitaxel drug-coated balloon angioplasty.

  • Informed Consent:

Patients have been fully informed about the nature and purpose of the study, and have voluntarily agreed to participate, with signed informed consent.

  • Physiological Status:

Cardiac function classified as NYHA I-III.

Exclusion criteria

  • Allergy History:

Known allergies to paclitaxel or any materials used in angioplasty (e.g., contrast agents).

  • Severe Complications:

Uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg).

  • Other Medical Conditions:

Active bleeding or clotting disorders.

  • Other serious diseases with a life expectancy of less than 1 year (e.g., advanced cancer).
  • Pregnancy or Nursing: Women who are currently pregnant or breastfeeding.
  • Participation in Other Studies: Currently participating in other clinical trials that might affect the results of this study.
  • Psychological or Behavioral Factors: History of psychiatric or behavioral disorders that could interfere with adherence to study protocols, or communication barriers that prevent understanding of study requirements.

Treatment and study plan

Primary outcomes

  1. MACE

    Time frame: 12 months

    cardiovascular adverse events:defined as death, Myocardial Infarction (MI, Q waves and non-Q waves), emergent cardiac bypass surgery, or any target lesion revascularization (repeat Percutaneous transluminal coronary angioplasty (PTCA) or Coronary artery bypass grafting (CABG)).

Secondary outcomes

  1. LLL(late lumen loss)

    Time frame: 12 months

    Detection by QCA technique by subtracting the minimum lumen diameter at review from the minimum lumen diameter in the immediate postoperative period

Study contacts

Contact information is provided by the study sponsor or research team.

Quan Guo, MD

CONTACT

[email protected]

+8615670510031

Sponsors and collaborators

Lead sponsor

Henan Institute of Cardiovascular Epidemiology

Other

Registry information

Acronym: RE-DCB

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Oct 1, 2024
Registry last updated
Nov 14, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.